[go: up one dir, main page]

SG10202109376YA - Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof - Google Patents

Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof

Info

Publication number
SG10202109376YA
SG10202109376YA SG10202109376YA SG10202109376YA SG 10202109376Y A SG10202109376Y A SG 10202109376YA SG 10202109376Y A SG10202109376Y A SG 10202109376YA SG 10202109376Y A SG10202109376Y A SG 10202109376YA
Authority
SG
Singapore
Prior art keywords
conjugates
self
peptide linkers
maytansinoid derivatives
immolative
Prior art date
Application number
Inventor
Wayne C Widdison
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of SG10202109376YA publication Critical patent/SG10202109376YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG10202109376Y 2017-02-28 2018-02-27 Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof SG10202109376YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762465118P 2017-02-28 2017-02-28
US201762480209P 2017-03-31 2017-03-31

Publications (1)

Publication Number Publication Date
SG10202109376YA true SG10202109376YA (en) 2021-10-28

Family

ID=61617182

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202109376Y SG10202109376YA (en) 2017-02-28 2018-02-27 Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof
SG11201907693VA SG11201907693VA (en) 2017-02-28 2018-02-27 Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201907693VA SG11201907693VA (en) 2017-02-28 2018-02-27 Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof

Country Status (13)

Country Link
US (3) US10792372B2 (en)
EP (1) EP3589328A1 (en)
JP (3) JP7106560B2 (en)
KR (2) KR102681168B1 (en)
CN (3) CN116785450A (en)
AU (2) AU2018229277B2 (en)
CA (1) CA3054608A1 (en)
IL (4) IL298414B2 (en)
MA (1) MA47815A (en)
RU (2) RU2765098C2 (en)
SG (2) SG10202109376YA (en)
TW (3) TW202506199A (en)
WO (1) WO2018160539A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2694106T1 (en) 2011-04-01 2018-04-30 Immunogen, Inc. Methods for increasing efficacy of folr1 cancer therapy
US10711032B2 (en) 2016-11-08 2020-07-14 Regeneron Pharmaceuticals, Inc. Steroids and protein-conjugates thereof
KR20200085807A (en) 2017-11-07 2020-07-15 리제너론 파마슈티칼스 인코포레이티드 Hydrophilic linker for antibody drug conjugates
WO2020014306A1 (en) * 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
CN111228508B (en) * 2018-11-29 2023-02-17 暨南大学 Multi-target anti-tumor polypeptide drug conjugate and preparation method and application thereof
JP2022527449A (en) * 2019-03-21 2022-06-02 イミュノジェン・インコーポレーテッド How to prepare a cell binder-drug complex
JP7585230B2 (en) * 2019-04-29 2024-11-18 イミュノジェン， インコーポレイテッド Biparatopic FR-α antibodies and immunoconjugates
TW202428257A (en) * 2022-09-15 2024-07-16 美商伊繆諾金公司 Methods for preparing maytansinoid derivatives with self-immolative peptide linkers
WO2025078841A2 (en) 2023-10-11 2025-04-17 Antikor Biopharma Limited Antibodies, conjugates, and uses thereof
WO2025094146A1 (en) 2023-11-02 2025-05-08 Immunogen Switzerland Gmbh Vasconstrictors for reducing ocular toxicity of antibody-maytansinoid conjugates

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2010129A (en) 1934-09-26 1935-08-06 Ingersoll Rand Co Valve assembly
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
PT1024191E (en) 1991-12-02 2008-12-22 Medical Res Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
DE69231123T2 (en) 1992-03-25 2001-02-15 Immunogen Inc Conjugates of cell-binding agents and derivatives of CC-1065
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US20080152586A1 (en) 1992-09-25 2008-06-26 Avipep Pty Limited High avidity polyvalent and polyspecific reagents
US6355780B1 (en) 1995-02-22 2002-03-12 Yeda Research And Development Co. Ltd. Antibodies to the death domain motifs of regulatory proteins
KR20000067963A (en) 1996-07-22 2000-11-25 죤 에이치. 뷰센 Thiol sulfone metalloprotease inhibitors
JP2002501721A (en) 1997-08-01 2002-01-22 モルフォシス・アクチェンゲゼルシャフト Novel method and phage for identifying nucleic acid sequences encoding members of multimeric (poly) peptide complexes
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
EP1242401B1 (en) 1999-11-24 2006-12-27 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
CN1215052C (en) * 2000-07-19 2005-08-17 三菱制药株式会社 Sulfonic acid derivatives of hydroxamic acids and their use as medicinal products
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US20030109682A1 (en) * 2001-09-07 2003-06-12 Daniel Santi Maytansines and maytansine conjugates
AU2002356844C1 (en) 2001-10-23 2010-03-04 Amgen Fremont Inc. PSMA antibodies and protein multimers
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
KR20050032110A (en) 2002-08-02 2005-04-06 이뮤노젠 아이엔씨 Cytotoxic agents containing novel potent taxanes and their therapeutic use
DE60336149D1 (en) 2002-08-16 2011-04-07 Immunogen Inc Highly reactive and soluble crosslinkers and their use in the preparation of conjugates for the targeted delivery of small-molecule drugs
ZA200503075B (en) 2002-11-07 2006-09-27 Immunogen Inc Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
HUE028314T2 (en) 2003-05-20 2016-12-28 Immunogen Inc Improved cytotoxic agents comprising new maytansinoids
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
MXPA06000830A (en) 2003-07-21 2006-04-18 Immunogen Inc A ca6 antigen-specific cytotoxic conjugate and methods of using the same.
US7834155B2 (en) 2003-07-21 2010-11-16 Immunogen Inc. CA6 antigen-specific cytotoxic conjugate and methods of using the same
US8039588B2 (en) 2004-05-21 2011-10-18 The Uab Research Foundation Variable lymphocyte receptors
RU2404810C9 (en) 2004-06-01 2015-06-20 Дженентек, Инк. Conjugates antibody-medicinal agent and methods
WO2006065533A2 (en) 2004-11-29 2006-06-22 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
DK1902131T3 (en) 2005-07-08 2010-03-01 Univ Zuerich Phage display using cotranslational translocation of fusion polypeptides
JP2009504193A (en) 2005-08-22 2009-02-05 イミュノジェン・インコーポレーテッド CA6 antigen-specific cytotoxic conjugate and method using the conjugate
US8623356B2 (en) 2005-11-29 2014-01-07 The University Of Sydney Demibodies: dimerization-activated therapeutic agents
EP1996612A4 (en) 2006-03-03 2010-10-20 Univ Kingston COMPOSITIONS FOR THE TREATMENT OF CANCERS
TWI523864B (en) 2006-05-30 2016-03-01 建南德克公司 Antibodies and immunoconjugates and uses therefor
EP2047252B1 (en) 2006-06-22 2013-01-23 Walter and Eliza Hall Institute of Medical Research Structure of the insulin receptor ectodomain
WO2009040338A1 (en) 2007-09-24 2009-04-02 University Of Zürich Designed armadillo repeat proteins
DK2281006T3 (en) 2008-04-30 2017-11-06 Immunogen Inc CROSS-BONDING AGENTS AND APPLICATIONS THEREOF
WO2009134952A2 (en) 2008-04-30 2009-11-05 Immunogen, Inc Potent conjugates and hydrophilic linkers
EA028304B1 (en) 2008-10-31 2017-11-30 Сентокор Орто Байотек Инк. Methods of constructing a library of a protein scaffold based on a fibronectin type iii (fn3) domain
GB0913775D0 (en) 2009-08-06 2009-09-16 Medical Res Council Multispecific peptides
JP5873335B2 (en) 2009-02-12 2016-03-01 ヤンセン バイオテツク，インコーポレーテツド Scaffold compositions, methods and uses based on fibronectin type III domains
JP2013514788A (en) 2009-12-23 2013-05-02 アビペップ ピーティーワイ リミテッド Immunoconjugate and production method 2
IL290617B2 (en) 2010-02-24 2023-11-01 Immunogen Inc Folate receptor 1 antibodies and immunoconjugates and uses thereof
SI2544719T1 (en) 2010-03-12 2019-11-29 Debiopharm Int Sa Cd37-binding molecules and immunoconjugates thereof
DK3569256T3 (en) 2010-04-30 2022-08-15 Janssen Biotech Inc STABILIZED FIBRONECTIN DOMAIN COMPOSITIONS, METHODS AND USES
WO2012058588A2 (en) 2010-10-29 2012-05-03 Immunogen, Inc. Novel egfr-binding molecules and immunoconjugates thereof
WO2012058592A2 (en) 2010-10-29 2012-05-03 Immunogen, Inc. Non-antagonistic egfr-binding molecules and immunoconjugates thereof
EP3545977A1 (en) * 2011-03-29 2019-10-02 ImmunoGen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
SI2694106T1 (en) 2011-04-01 2018-04-30 Immunogen, Inc. Methods for increasing efficacy of folr1 cancer therapy
AU2012272930B2 (en) * 2011-06-21 2015-06-11 Immunogen, Inc. Novel maytansinoid derivatives with peptide linker and conjugates thereof
NL2009825C2 (en) 2012-11-16 2014-05-21 Ipee Bvba Sanitary appliance and method of determining use thereof.
CN103333179B (en) * 2012-12-21 2017-06-16 百奥泰生物科技(广州)有限公司 Class maytansine derivative and its production and use
SI2953976T1 (en) 2013-02-08 2021-08-31 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
HK1219423A1 (en) * 2013-02-28 2017-04-07 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
WO2014176284A1 (en) 2013-04-22 2014-10-30 Avelas Biosciences, Inc. Selective drug delivery compositions and methods of use
WO2014194030A2 (en) * 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
WO2015038426A1 (en) * 2013-09-13 2015-03-19 Asana Biosciences, Llc Self-immolative linkers containing mandelic acid derivatives, drug-ligand conjugates for targeted therapies and uses thereof
CA2932647C (en) 2013-12-19 2022-06-14 Seattle Genetics, Inc. Methylene carbamate linkers for use with targeted-drug conjugates
KR102557615B1 (en) * 2014-06-06 2023-07-20 레드우드 바이오사이언스 인코포레이티드 Anti-her2 antibody-maytansine conjugates and methods of use thereof
AU2015312075A1 (en) * 2014-09-03 2017-03-09 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
WO2016094455A1 (en) 2014-12-08 2016-06-16 Sorrento Therapeutics, Inc. C-met antibody drug conjugate
DK3313884T3 (en) 2015-06-29 2021-02-22 Immunogen Inc ANTI-CD123 ANTIBODIES AND CONJUGATES AND THEIR DERIVATIVES
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof

Also Published As

Publication number Publication date
MA47815A (en) 2020-01-08
US20220111067A1 (en) 2022-04-14
EP3589328A1 (en) 2020-01-08
TWI862991B (en) 2024-11-21
AU2025204489A1 (en) 2025-07-10
CN116785450A (en) 2023-09-22
AU2018229277A1 (en) 2019-10-10
CN110366431B (en) 2023-07-18
JP7645843B2 (en) 2025-03-14
US10792372B2 (en) 2020-10-06
IL298414B2 (en) 2024-12-01
KR20240110082A (en) 2024-07-12
RU2019129839A (en) 2021-03-30
JP2025087787A (en) 2025-06-10
IL290698A (en) 2022-04-01
KR20190122766A (en) 2019-10-30
JP2022137200A (en) 2022-09-21
IL298414A (en) 2023-01-01
TW202320794A (en) 2023-06-01
IL298414B1 (en) 2024-08-01
IL290698B (en) 2022-12-01
IL268921A (en) 2019-10-31
IL268921B (en) 2022-03-01
RU2022101392A (en) 2022-03-02
IL290698B2 (en) 2023-04-01
RU2765098C2 (en) 2022-01-25
CN110366431A (en) 2019-10-22
IL313912A (en) 2024-08-01
AU2018229277B2 (en) 2025-03-20
JP7106560B2 (en) 2022-07-26
TW202506199A (en) 2025-02-16
TWI781145B (en) 2022-10-21
US11135308B2 (en) 2021-10-05
TW201838657A (en) 2018-11-01
RU2019129839A3 (en) 2021-06-24
SG11201907693VA (en) 2019-09-27
KR102681168B1 (en) 2024-07-04
CA3054608A1 (en) 2018-09-07
JP2020510656A (en) 2020-04-09
US20200197531A1 (en) 2020-06-25
WO2018160539A1 (en) 2018-09-07
US20180296694A1 (en) 2018-10-18
CN116785451A (en) 2023-09-22

Similar Documents

Publication Publication Date Title
SG10202109376YA (en) Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof
IL277748A (en) Camptothecin peptide conjugates
ZA201805853B (en) Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
IL266310A (en) Peptide-containing linkers for antibody-drug conjugates
IL287391A (en) Amatoxin antibody-drug conjugates and uses thereof
EP3334462B8 (en) Covalent linkers in antibody-drug conjugates and methods of making and using the same
IL254258A0 (en) Cryptophycin-based antibody-drug conjugates with novel self-immolative linkers
ZA201902190B (en) Non-linear self-immolative linkers and conjugates thereof
EP3695852A4 (en) Anti-mesothelin antibody and antibody-drug conjugate thereof
IL282414A (en) Cysteine engineered antibody-drug conjugates with peptide-containing linkers
IL272987A (en) Mutant fgf-21 peptide conjugates and uses thereof
SG11202106067UA (en) Tubulysins and protein-tubulysin conjugates
SG11202106658XA (en) Rifamycin analogs and antibody-drug conjugates thereof
IL275208A (en) Hsp90-targeting conjugates and formulations thereof
IL266112A (en) Anti-edb antibodies and antibody-drug conjugates
EP3666788A4 (en) Hemiasterlin derivatives and antibody-drug conjugates including same
SG11202101517PA (en) Isoquinoline-steroid conjugates and uses thereof
IL268245A (en) Calicheamicin derivatives and antibody drug conjugates thereof
IL291312A (en) Anti-ptcra antibody-drug conjugates and uses thereof
ES2974288T9 (en) Antibody-drug conjugates including hemiasterlin derivative
EP3856258C0 (en) Sulfomaleimide-based linkers and corresponding conjugates
GB201806022D0 (en) Pyrrolobenzodiazepines and conjugates thereof
HK40015827A (en) Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof
HK40104461A (en) Hemiasterlin derivatives and antibody-drug conjugates including same
HK40050732A (en) Cysteine engineered antibody-drug conjugates with peptide-containing linkers